Creative Planning increased its stake in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 0.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,744 shares of the biotechnology company’s stock after buying an additional 54 shares during the period. Creative Planning’s holdings in Five Prime Therapeutics were worth $203,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Laurion Capital Management LP bought a new position in Five Prime Therapeutics during the first quarter valued at about $210,000. BlueCrest Capital Management Ltd bought a new position in Five Prime Therapeutics during the first quarter valued at about $254,000. Arxis Securities LLC bought a new position in Five Prime Therapeutics during the first quarter valued at about $267,000. Tudor Investment Corp ET AL raised its position in Five Prime Therapeutics by 56.8% in the first quarter. Tudor Investment Corp ET AL now owns 8,033 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 2,910 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Five Prime Therapeutics by 39.2% in the first quarter. Legal & General Group Plc now owns 9,168 shares of the biotechnology company’s stock valued at $331,000 after buying an additional 2,583 shares during the last quarter. Institutional investors and hedge funds own 85.10% of the company’s stock.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) traded up 1.87% on Tuesday, hitting $30.44. The stock had a trading volume of 48,085 shares. Five Prime Therapeutics, Inc. has a 1-year low of $26.65 and a 1-year high of $60.98. The firm’s market capitalization is $849.18 million. The stock’s 50-day moving average is $29.82 and its 200 day moving average is $35.52.

TRADEMARK VIOLATION NOTICE: “Creative Planning Purchases 54 Shares of Five Prime Therapeutics, Inc. (FPRX)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/08/creative-planning-purchases-54-shares-of-five-prime-therapeutics-inc-fprx.html.

Several equities analysts recently issued reports on FPRX shares. Zacks Investment Research upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Wednesday, April 26th. Jefferies Group LLC restated a “buy” rating and set a $55.00 price target on shares of Five Prime Therapeutics in a research report on Thursday, June 8th. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $60.83.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.